AVAVA: Pioneering the Future of Medical Aesthetics with $35 Million in Funding

June 20, 2024, 3:44 am
AVAVA
EnergyTechHardwarePlatformProductResearchSkinSpace
Total raised: $35M
AVAVA, a cutting-edge medical aesthetics platform company based in Waltham, Massachusetts, has recently made waves in the industry by securing a substantial $35 million in funding. This financial boost, comprising $25 million from a mix of new and existing investors, including the strategic partner Jeisys Medical, Inc, and an additional $10 million from Catalio Capital Management, marks a significant milestone for the company.

At the forefront of AVAVA's innovative offerings is MIRIA, a revolutionary aesthetic dermatology laser that leverages proprietary Focal Point Technology™ to deliver energy with pinpoint accuracy throughout the skin. This groundbreaking technology enhances skin revitalization outcomes for patients of all skin tones, setting a new standard in personalized skin care.

Under the leadership of CEO Dr. Irina Erenburg, AVAVA is spearheading a new era in intradermal lasers, enabling customization through a unique mapping approach and patented Focal Point Technology™. By utilizing advanced skin imaging techniques, AVAVA ensures that laser energy is delivered at the precise therapeutic depth, optimizing results for individuals with diverse skin tones and types.

The recent funding injection will not only accelerate the commercialization of MIRIA but also support AVAVA's ambitious global expansion plans, approved by the company's board of directors. With a pipeline of innovative products in development, AVAVA is poised to further solidify its position as a trailblazer in the medical aesthetics industry.

Founded by esteemed scientific pioneers Dr. R. Rox Anderson, Dr. Dieter Manstein, and Dr. Henry Chan, AVAVA's platform represents a paradigm shift in the field of medical aesthetics. By offering safe and effective solutions for individuals with varying skin tones, AVAVA's commitment to precision energy delivery while minimizing collateral damage has garnered widespread acclaim.

In a statement regarding the funding, Dr. Irina Erenburg expressed enthusiasm for AVAVA's continued growth and innovation, emphasizing the company's dedication to revolutionizing the aesthetics industry. Collaborating with esteemed partners like Catalio and Jeisys, AVAVA is poised to redefine the landscape of medical aesthetics, delivering best-in-class treatments to individuals in need.

Similarly, Jonathan Blankfein, Partner & Portfolio Manager at Catalio Capital Management, highlighted the firm's excitement in partnering with AVAVA, recognizing the company's remarkable progress and disruptive approach to healthcare technologies. As a long-term strategic partner, Catalio is optimistic about AVAVA's future and the burgeoning opportunities within the aesthetics industry.

With its visionary leadership, groundbreaking technology, and unwavering commitment to innovation, AVAVA is poised to shape the future of medical aesthetics, setting new standards for personalized skin care and revolutionizing the industry as we know it.